GLP-1 (S) is studied to better understand blood sugar regulation, insulin signaling, appetite-related brain pathways, and incretin hormone biology

GLP-1 belongs to the glucagon peptide superfamily and is released from intestinal L-cells following nutrient exposure. What distinguishes it as a research compound is the glucose-dependent nature of its insulinotropic activity receptor activation alone does not trigger insulin release unless sufficient glucose is present, a built-in signaling gate that makes it a precise and controllable tool for studying pancreatic beta-cell biology.

Beyond pancreatic signaling, GLP-1R is expressed across multiple tissue types including hypothalamic neurons, cardiac tissue, and the gastrointestinal tract  broadening the compound’s relevance across metabolic, appetite regulation, and cardiovascular signaling research. Its short active half-life in biological preparations also makes it a useful comparator compound when benchmarking longer-acting GLP-1R agonist analogs in stability and receptor occupancy studies.

All product supplied through this repository is intended exclusively for controlled laboratory settings. It is not formulated for human or veterinary administration.

• CAS Number: 107444-51-9
• Molecular Weight: 3297.68 Da
• Purity: ≥99%
• Also Known As: GLP-1, Glucagon-Like Peptide-1, GLP-1(7-36) amide, GLP-1(7-37) Incretin hormone
• Chemical Formula: C₁₄₉H₂₂₅N₄₃O₄₇

In cell-based and preclinical models, GLP-1(7-36) amide binds to GLP-1R and activates adenylyl cyclase through Gs-protein coupling, rapidly increasing intracellular cAMP within 60 seconds of receptor engagement at physiological concentrations of 0.1–10 nM. Downstream PKA activation leads to KATP channel closure and L-type calcium channel activation, triggering insulin granule exocytosis from pancreatic beta-cell preparations — but only in the presence of glucose concentrations above 5.5 mM, confirming the glucose-gated nature of this insulinotropic mechanism.

Glucagon suppression represents a second, distinct signaling arm. Research using isolated perfused pancreas and sorted alpha-cell preparations has established that GLP-1 does not suppress glucagon secretion through direct alpha-cell receptor engagement. Instead, it operates through a paracrine mechanism — stimulating delta-cell somatostatin release, which then suppresses alpha-cell glucagon output via somatostatin receptor 2 signaling. Blocking somatostatin signaling abolishes this effect entirely, confirming the indirect pathway.

Together, these two mechanisms — direct beta-cell cAMP signaling and indirect paracrine glucagon suppression — make GLP-1 a well-characterized dual-action tool compound for incretin biology research.

• GLP-1 Receptor Characterization
• Glucose-Dependent Insulin Signaling
• Incretin Biology Research
• Paracrine Signaling Studies
• Appetite and Hypothalamic Signaling
• Beta-Cell Exocytosis Modeling
• GLP-1R Agonist Benchmarking